Chemical subgroup
J05AP – Antivirale Mittel zur Behandlung von Hepatitis C Infektionen
18Decisions
76Patient groups
Added benefit by patient group
- Considerable13
- Minor14
- Non-quantifiable9
- Not proven40
Decisions, newest first
- 2022-08-04EpclusaSofosbuvir/VelpatasvirNot proven
- 2022-05-05ZepatierElbasvir/GrazoprevirNot proven
- 2022-04-07VoseviSofosbuvir/Velpatasvir/VoxilaprevirNot proven
- 2021-12-16MaviretGlecaprevir/PibrentasvirNot proven: 2 of 2 patient groups
- 2021-04-01EpclusaSofosbuvir/VelpatasvirNot proven: 4 of 4 patient groups
- 2021-01-21HarvoniLedipasvir/SofosbuvirNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-01-21SovaldiSofosbuvirNon-quantifiable
- 2019-10-17MaviretGlecaprevir/PibrentasvirNot proven: 2 of 2 patient groups
- 2018-04-05SovaldiSofosbuvirNon-quantifiable: 2 of 2 patient groups
- 2018-02-15HarvoniLedipasvir/SofosbuvirNon-quantifiable: 2 of 4 patient groupsNot proven: 2 of 4 patient groups
- 2018-02-15VoseviSofosbuvir/Velpatasvir/VoxilaprevirNot proven: 6 of 6 patient groups
- 2018-02-01MaviretGlecaprevir/PibrentasvirNot proven: 7 of 7 patient groups
- 2017-06-15ZepatierElbasvir/GrazoprevirNot proven: 2 of 2 patient groups
- 2017-01-05EpclusaSofosbuvir/VelpatasvirConsiderable: 1 of 9 patient groupsMinor: 1 of 9 patient groupsNon-quantifiable: 1 of 9 patient groupsNot proven: 6 of 9 patient groups
- 2015-07-16ViekiraxOmbitasvir/Paritaprevir/RitonavirConsiderable: 4 of 9 patient groupsMinor: 4 of 9 patient groupsNot proven: 1 of 9 patient groups
- 2015-07-16ExvieraDasabuvirConsiderable: 4 of 7 patient groupsMinor: 3 of 7 patient groups
- 2015-05-21HarvoniLedipasvir/SofosbuvirConsiderable: 3 of 7 patient groupsMinor: 1 of 7 patient groupsNon-quantifiable: 2 of 7 patient groupsNot proven: 1 of 7 patient groups
- 2014-07-17SovaldiSofosbuvirConsiderable: 1 of 9 patient groupsMinor: 5 of 9 patient groupsNot proven: 3 of 9 patient groups
Data status: 2026-10-29